,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2023', 'fs': 'May 2023', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000NoosP2AR'}, 'Id': 'a0POZ00000NoosP2AR', 'Event_Date__c': '2023-05-12', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2023', 'Status_History__c': 'a132P000000EDtAQAW'}, 'change': None}]",May 2023,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2023', 'fs': 'May 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000NoosQ2AR'}, 'Id': 'a0POZ00000NoosQ2AR', 'Event_Date__c': '2023-05-15', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2023', 'Status_History__c': 'a132P000000EDtFQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 21 July 2023', 'fs': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 21 July 2023', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000NoosR2AR'}, 'Id': 'a0POZ00000NoosR2AR', 'Event_Date__c': '2023-07-07', 'Event_Description__c': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Friday 21 July 2023', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a13OZ000003nN6fYAE'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee recommended that zanubrutinib for the treatment of individuals with relapsed/refractory Waldenström macroglobulinaemia be listed with a <strong>medium</strong> priority within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Zanubrutinib</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application – relapsed/refractory Waldenström macroglobulinaemia (Lymphoplasmacytic Lymphoma)</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Prerequisites</strong><span style=""font-size: 9pt;""> (tick boxes where appropriate):</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has Waldenström Macroglobulinaemia/Lymphoplasmacytic Lymphoma requiring treatment; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has relapsed after, or is refractory to, previous line of treatment; and </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient is zanubrutinib naïve; and </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has good performance status.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal application</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Prerequisites</strong><span style=""font-size: 9pt;""> (tick boxes where appropriate) </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of clinical disease progression and </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate, and the patient is benefiting from treatment.</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The health need for those experiencing relapsed/refractory (R/R) WM including those experiencing early relapse/refractory disease who have fewer treatment options following first line treatment.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The health benefit evidence and improved tolerability and safety of zanubrutinib compared to currently funded treatments for peoples with WM.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The improved suitability of an oral treatment option for individuals if used as a monotherapy.</p><p><br></p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee recommended that zanubrutinib for the treatment of individuals with relapsed/refractory Waldenström macroglobulinaemia be listed with a <strong>medium</strong> priority within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Zanubrutinib</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application – relapsed/refractory Waldenström macroglobulinaemia (Lymphoplasmacytic Lymphoma)</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Prerequisites</strong><span style=""font-size: 9pt;""> (tick boxes where appropriate):</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has Waldenström Macroglobulinaemia/Lymphoplasmacytic Lymphoma requiring treatment; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has relapsed after, or is refractory to, previous line of treatment; and </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient is zanubrutinib naïve; and </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has good performance status.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal application</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Prerequisites</strong><span style=""font-size: 9pt;""> (tick boxes where appropriate) </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of clinical disease progression and </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate, and the patient is benefiting from treatment.</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The health need for those experiencing relapsed/refractory (R/R) WM including those experiencing early relapse/refractory disease who have fewer treatment options following first line treatment.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The health benefit evidence and improved tolerability and safety of zanubrutinib compared to currently funded treatments for peoples with WM.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The improved suitability of an oral treatment option for individuals if used as a monotherapy.</p><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<p><em>Māori impact</em></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, based on the supplier-provided analysis of Manatū Hauora- New Zealand Cancer Registry data, Māori comprised roughly 3% of registered cases of WM between 2010 to 2020. The Committee considered there to be a lack of evidence to suggest there was a difference in age-standardised incidence or disease biology for Māori individuals compared to non-Māori individuals with WM in New Zealand.</p><p><em>Background</em></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that at the November 2021 CaTSoP (now CTAC) meeting an application for ibrutinib, a first-generation Bruton’s tyrosine kinase inhibitor (BTKi) which is used as a continuous monotherapy for the treatment of WM was assessed and two recommendations were made. The Committee noted that CaTSoP recommended that ibrutinib for the treatment of first line and R/R WM be listed with a low and medium priority, respectively.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that at the October 2022 CTAC meeting an application for bortezomib, a proteosome inhibitor, which is used for a fixed duration in combination with other drugs for the treatment of WM, was assessed and bortezomib for the treatment of WM in the R/R setting was recommended to be listed with a medium priority. </p><p>Health need</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that WM is an incurable lymphoplasmacytic lymphoma infiltration of lymphoplasmacytic cells into the bone marrow and immunoglobulin M (IgM) monoclonal gammopathy. The Committee noted that WM is a relatively uncommon blood cancer, representing 2% of blood cancer cases. The Committee noted a supplier-provided analysis of Manatū Hauora- New Zealand Cancer Registry data, which suggested that in 2020, there were 40 newly diagnosed cases of WM in New Zealand. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the mean age of diagnosis with WM was roughly 68 years. The Committee noted that treatment is not required until the individual is experiencing symptoms, with a median time between diagnosis and\xa0treatment can be up to 5 to 10 years (<a href=""https://ashpublications.org/blood/article/119/19/4462/29975/Progression-in-smoldering-Waldenstrom"" target=""_blank"">Kyle et al. Blood. 2012;119:4462-6</a>). The Committee noted that there is an unmet health need for individuals who are unable to receive bendamustine-rituximab (BR) therapy, a relatively effective treatment for the condition but one that is typically reserved for people experiencing <a href=""https://jamanetwork.com/journals/jamaoncology/fullarticle/2432463"" target=""_blank"">good performance status</a>. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the currently funded treatment options for WM include BR, cyclophosphamide-dexamethasone-rituximab (CDR), rituximab-cyclophosphamide-vincristine-prednisone (R-CVP), cyclophosphamide-doxorubicin, vincristine, prednisone + rituximab (R-CHOP), rituximab-chlorambucil (R-Chlorambucil) and rituximab monotherapy. The Committee noted that BR is the preferred and most efficacious current treatment option for people experiencing <a href=""https://jamanetwork.com/journals/jamaoncology/fullarticle/2432463"" target=""_blank"">good performance status</a>, the other treatment regimens used in situations where BR is not a suitable option. </p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, based on the supplier-provided analysis of Manatū Hauora- New Zealand Cancer Registry data, Māori comprised roughly 3% of registered cases of WM between 2010 to 2020. The Committee considered there to be a lack of evidence to suggest there was a difference in age-standardised incidence or disease biology for Māori individuals compared to non-Māori individuals with WM in New Zealand.</p><p><em>Health benefit</em></p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the following evidence of the progression-free survival (PFS) that the currently funded treatment options can provide: </p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>BR can provide a median PFS of up to 69.5 months (<a href=""https://pubmed.ncbi.nlm.nih.gov/23433739/"" target=""_blank"">Rummel et al. Lancet. 2013;381:1203-103</a>).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>CDR can provide a median PFS of up to 34 months in the first-line setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/26359434/"" target=""_blank"">Kastritis et al. Blood). 2015;126:1392-4</a>) and up to 35 month in the R/R setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/28786474/"" target=""_blank"">Paludo et al. Br J Haematol. 2017;179:98-105</a>).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>R-CVP/R-CHOP can provide a median PFS of up to 30 months in the upfront setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/23433739/"" target=""_blank"">Rummel et al. Lancet. 2013;381:1203-103</a>).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>R-monotherapy can provide a median PFS of up to 20 months in the upfront setting and 20 months in the R/R setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/29856685/"" target=""_blank"">Dimopoulas et al N Engl J Med. 2018;378:2399-2410</a>).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that zanubrutinib is a second-generation inhibitor of Bruton’s tyrosine kinase (BTKi). Zanubrutinib binds with high affinity to the BTK target site, forming an irreversible covalent bond, thus preventing further BTK-mediated activity, hindering malignant B-cell proliferation and differentiation.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there is limited evidence to support the use of zanubrutinib in the first-line setting, with only 20 of the 201 participants in ASPEN receiving zanubrutinib in the first-line setting and the remaining participants having relapsed/refractory disease (<a href=""https://pubmed.ncbi.nlm.nih.gov/32731259/"" target=""_blank"">Tam et al. Blood. 2020;136:2038-50</a>; <a href=""https://pubmed.ncbi.nlm.nih.gov/32698195/"" target=""_blank"">Trotman et al. Blood. 2022;136:2027-37</a>). </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee previously considered there to be a class effect between BTKi therapies for the treatment of WM. The Committee considered that, based on the available evidence, both ibrutinib and zanubrutinib appeared to provide similar magnitudes of health benefit and similarly favourable safety profiles compared to funded chemotherapies. </p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there is no evidence of a difference in efficacy between zanubrutinib and ibrutinib. The Committee noted that there were greater rates of partial response rates when the individuals received zanubrutinib compared with ibrutinib, however the Committee considered that the response rate measure is not prognostic in WM and therefore did not translate into the PFS or OS benefit. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the supplier’s proposed treatment paradigms for individuals requiring first-line and R/R treatment for WM but considered both to be unsuitable. In regard to first line, the Committee considered that treatment options depend on whether BR is either going to be suitable or unsuitable for the individual, and that if BR was deemed unsuitable alternative options for individuals could include CDR, R-CVP, R-monotherapy or a BTKi if it was available. In regard to the R/R treatment setting, the Committee noted that less than 10% of individuals would receive retreatment of BR and that the preferred option for all individuals following first line immunochemotherapy would be a BTKi if it was available.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the ASPEN trial was a phase III randomised, double-blind, placebo-control trial comparing zanubrutinib monotherapy with rituximab monotherapy in 201 individuals with WM previously untreated (n=37) and treated (n=164) (<a href=""https://pubmed.ncbi.nlm.nih.gov/32731259/"" target=""_blank"">Tam et al. Blood. 2020; 146:2038-50</a>). </p><p class=""ql-indent-1"">1.14.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that individuals participating in the trial had to have received at least one prior line of treatment, or if individuals were treatment naïve, it was due to immunochemotherapy being inappropriate, and were reported to be due to cardiac, renal, infection or other reasons. Individuals had the <em>MYD88</em> mutation which is representative of over 90% of those with WM, however individuals with the wildtype gene or genetic testing were indeterminate received zanubrutinib in a non-randomised arm of the study (<a href=""https://pubmed.ncbi.nlm.nih.gov/33284944/"" target=""_blank"">Dimopoulos et al. Blood Adv. 2020:4 6009-18</a>). </p><p class=""ql-indent-1"">1.14.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the results of the final analysis of the ASPEN trial, where after a median follow up of 19.4 months, 79% of individuals remained on study treatment, and 89% remained on study. No individuals experienced a complete response. Overall 28% zanubrutinib group and 19% ibrutinib group (2-sided, p=0.09), 29% zanubrutinib group and 20% ibrutinib group (p =0.12) of the R/R group and 26% zanubrutinib group and 17% ibrutinib group (p =0.54) TN group were reported to experience a very good partial response, which was defined as monoclonal IgM detectable, ≥90% reduction in serum IgM level from baseline or normal serum IgM values, improvement in lymphadenopathy/splenomegaly if present at baseline, no new signs, or symptoms of active disease. The median time to experience the very good partial response was 4.7 months zanubrutinib and 5.1 months ibrutinib (p=0.17) for the R/R group and 5.6 months zanubrutinib and 22.1 months ibrutinib (p=0.35) for the TN group. The 18-month progression-free survival was reported to be 85% zanubrutinib and 84% ibrutinib and 18-month survival rate was 97% zanubrutinib and 93% ibrutinib. </p><p class=""ql-indent-1"">1.14.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the results of the toxicity and safety analysis of the ASPEN trial and noted that the incidence of adverse events involving atrial fibrillation/flutter, diarrhoea, contusion, muscle spasms, peripheral oedema and pneumonia occurred at ≥10% higher rates in individuals receiving ibrutinib compared with zanubrutinib and the incidence of neutropenia was ≥10% higher in individuals receiving zanubrutinib. The Committee noted that the higher incidence of neutropenia did not translate into a higher infection rate. </p><p class=""ql-indent-1"">1.14.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the long-term follow-up study of the ASPEN trial and noted that ibrutinib was associated with 19.4% of individuals experiencing an adverse event leading to discontinuation compared to 14.3% of individuals receiving zanubrutinib. The Committee noted the following proportions of individuals receiving either zanubrutinib or ibrutinib who experienced\xa0atrial fibrillation (7.9% zanubrutinib; 23.5% ibrutinib), diarrhoea (21.8% zanubrutinib; 34.7% ibrutinib), haemorrhage (55.4% zanubrutinib; 62.2% ibrutinib), major bleeding (7.9% zanubrutinib; 12.2% ibrutinib), hypertension (14.9% zanubrutinib; 25.5% ibrutinib), muscle spasm (10.9% zanubrutinib; 28.6% ibrutinib), localised infection (1.0% zanubrutinib; 11.2% ibrutinib), neutropenia (33.7% zanubrutinib; 19.4% ibrutinib), pneumonia (5% zanubrutinib; 18.4% ibrutinib), infection (grade ≥3) (78.2% zanubrutinib; 79.6% ibrutinib) (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430776/"" target=""_blank"">Dimopoulos et al. Hemasphere. 2922;6:1048-9</a>).</p><p class=""ql-indent-1"">1.14.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the results of the non-randomised arm of the ASPEN trial, and noted that 27% individuals with <em>MYD88 </em>wild-type were reported to have experienced a very good partial response when receiving zanubrutinib (<a href=""https://pubmed.ncbi.nlm.nih.gov/33284944/"" target=""_blank"">Dimopoulos et al. Blood Adv. 2020:4 6009-18</a>). The Committee noted that compared to <em>MYD88 </em>mutant WM individuals with <em>MYD88</em> wild type WM experienced lower rates of very good partial response. The Committee noted that Phase II study treating individuals with <em>MYD88</em> wild type WM with ibrutinib, and noted that individuals received less health benefit compared to individuals with <em>MYD88</em> mutant WM (<a href=""https://pubmed.ncbi.nlm.nih.gov/32931398/"" target=""_blank"" style=""font-size: 10pt;"">Treon et al. J Clin Oncol. 2021;39:565-575</a>). The Committee noted that the evidence was limited due to the small number of individuals with <em>MYD88</em> wild type WM, however considered that overall individuals with <em>MYD88</em> wild type WM receive less health benefit when receiving an BTKi therapy. </p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that there is high-quality evidence for what is a rare disease supporting the efficacy of zanubrutinib in the R/R setting. The Committee considered the evidence supporting the efficacy of zanubrutinib in the first line setting to be of lower quality due to the smaller number of participants in the ASPEN trial. The Committee considered that there was no evidence to suggest that zanubrutinib is inefficacious in the treatment naïve setting. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that BTKis have better safety profiles when compared to immunochemotherapy for the treatment of WM, however the Committee noted zanubrutinib has lower incidence of adverse events, highlighting the lower risk of atrial fibrillation/flutter in comparison to ibrutinib to be of particular importance as individuals with WM are usually older and more likely to be predisposed to atrial fibrillation/flutter. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the clinician-lead supporting submission requesting BTKi funding for individuals who are younger than 55 years old who relapse within five years of first-line immunochemotherapy and noted that requiring a second-line of treatment before the age of 55 years old is a rare situation. The Committee considered there to be a high probably that the disease course in this setting is more aggressive and considered the proposed SA criteria for individuals with R/R WM would be inclusive and appropriate for this situation. </p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that zanubrutinib would provide a health benefit to family, whānau and wider society, by allowing an individual to receive zanubrutinib at home, the lower toxicity profile, reducing the need to travel for individuals in rural areas, more time with family and whānau, and reduced chair time in chemotherapy units or hospital admission.</p><p><em>Suitability</em></p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that zanubrutinib is an oral medication that is administered twice daily. The Committee noted that funding zanubrutinib could reduce the need for individuals to travel to receive therapy at infusion facilities, as the funding alternatives to zanubrutinib are administered as infusions.</p><p><em>Cost and savings</em></p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that, based on the supplier-provided analysis of Manatū Hauora-New Zealand Cancer Registry data, there were an estimated 20 to 50 cases of newly diagnosed cases of WM per year in New Zealand and that the average annual growth in new cases over the period 2010 to 2020 was roughly 7% per annum.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the median time from diagnosis of WM to needing treatment is 5 to 10 years (<a href=""https://pubmed.ncbi.nlm.nih.gov/22451426/"" target=""_blank"">Kyle et al. Blood. 2012;119:4462-6</a>). The Committee noted that, due to the long natural history of the disease, and the population with WM being predominantly older adults, some individuals are dying from other causes.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the supplier’s estimate that 87% of newly diagnosed cases of WM would require treatment and noted this was based on a Spanish observational study of cases of WM who had IgM paraprotein concentrations of &gt;30g/L and percentage of clonal lymphocytes of &gt;20% in the marrow (<a href=""https://pubmed.ncbi.nlm.nih.gov/11736938/"" target=""_blank"">García-Sanz. Br J Haematol. 2001;115:575-82</a>). The Committee noted that a diagnosis of WM requires the proportion of clonal lymphocytes in the bone marrow to be &gt;10%, and there were no diagnostic criteria related to IgM paraprotein concentration. As such, the Committee considered that this cohort study was unlikely to be representative of the population with WM in New Zealand.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a previous CTAC discussion in October 2022, in the context of bortezomib for WM, that between 40 to 70 individuals with newly diagnosed or relapsed refractory WM could be eligible for treatment per year. The Committee considered those estimates could be appropriately applied to zanubrutinib for WM, noting these funding applications targeted the same population.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that zanubrutinib was unlikely to be used in combination with rituximab, as there was a lack of evidence that a zanubrutinib-rituximab combination would be any more efficacious than zanubrutinib alone. </p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered a cost-utility analysis submitted by the supplier which used rituximab monotherapy (R) as the comparator treatment for zanubrutinib in the first line setting and BR as the comparator in the relapsed/refractory setting. The Committee considered that the supplier-modelled comparators were not representative of the currently funded alternatives to zanubrutinib in either setting.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that, in a first line setting, zanubrutinib would most likely be considered for people with WM where BR chemotherapy is not suitable. The Committee considered that BR would not be suitable in approximately 40% of people requiring first-line treatment for WM. The Committee noted that currently either RCVP or CDR is the preferred treatment for those in which first-line BR is not suitable, with a roughly equal proportion of individuals between the two regimens. </p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that BR re-treatment would be suitable for less than 10% of people with relapsed/refractory WM, and that zanubrutinib would likely be considered for this group (regardless of performance status). The Committee noted that currently R, RCVP, or CDR are the preferred treatments for those in which second-line BR is not suitable, with a roughly equal proportion of individuals between the three regimens. </p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there was a modelled overall survival benefit in the supplier-provided cost-utility analyses for zanubrutinib. The Committee considered that there was limited overall survival data from ASPEN and relevant trials of comparators, and the available data did not indicate an apparent overall survival benefit associated with zanubrutinib. \xa0</p><p><em>Summary for assessment</em></p><p>1.29.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for zanubrutinib if it were to be funded in New Zealand for WM. </span>This<span style=""color: black;""> PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""font-size: 12px;"">PICO for zanubrutinib if it were to be funded in New Zealand for WM.\xa0\xa0</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000NoosS&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000aBD4"" alt=""image.png""></img></p>', 'fs': '<p><em>Māori impact</em></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, based on the supplier-provided analysis of Manatū Hauora- New Zealand Cancer Registry data, Māori comprised roughly 3% of registered cases of WM between 2010 to 2020. The Committee considered there to be a lack of evidence to suggest there was a difference in age-standardised incidence or disease biology for Māori individuals compared to non-Māori individuals with WM in New Zealand.</p><p><em>Background</em></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that at the November 2021 CaTSoP (now CTAC) meeting an application for ibrutinib, a first-generation Bruton’s tyrosine kinase inhibitor (BTKi) which is used as a continuous monotherapy for the treatment of WM was assessed and two recommendations were made. The Committee noted that CaTSoP recommended that ibrutinib for the treatment of first line and R/R WM be listed with a low and medium priority, respectively.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that at the October 2022 CTAC meeting an application for bortezomib, a proteosome inhibitor, which is used for a fixed duration in combination with other drugs for the treatment of WM, was assessed and bortezomib for the treatment of WM in the R/R setting was recommended to be listed with a medium priority. </p><p>Health need</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that WM is an incurable lymphoplasmacytic lymphoma infiltration of lymphoplasmacytic cells into the bone marrow and immunoglobulin M (IgM) monoclonal gammopathy. The Committee noted that WM is a relatively uncommon blood cancer, representing 2% of blood cancer cases. The Committee noted a supplier-provided analysis of Manatū Hauora- New Zealand Cancer Registry data, which suggested that in 2020, there were 40 newly diagnosed cases of WM in New Zealand. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the mean age of diagnosis with WM was roughly 68 years. The Committee noted that treatment is not required until the individual is experiencing symptoms, with a median time between diagnosis and\xa0treatment can be up to 5 to 10 years (<a href=""https://ashpublications.org/blood/article/119/19/4462/29975/Progression-in-smoldering-Waldenstrom"" target=""_blank"">Kyle et al. Blood. 2012;119:4462-6</a>). The Committee noted that there is an unmet health need for individuals who are unable to receive bendamustine-rituximab (BR) therapy, a relatively effective treatment for the condition but one that is typically reserved for people experiencing <a href=""https://jamanetwork.com/journals/jamaoncology/fullarticle/2432463"" target=""_blank"">good performance status</a>. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the currently funded treatment options for WM include BR, cyclophosphamide-dexamethasone-rituximab (CDR), rituximab-cyclophosphamide-vincristine-prednisone (R-CVP), cyclophosphamide-doxorubicin, vincristine, prednisone + rituximab (R-CHOP), rituximab-chlorambucil (R-Chlorambucil) and rituximab monotherapy. The Committee noted that BR is the preferred and most efficacious current treatment option for people experiencing <a href=""https://jamanetwork.com/journals/jamaoncology/fullarticle/2432463"" target=""_blank"">good performance status</a>, the other treatment regimens used in situations where BR is not a suitable option. </p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, based on the supplier-provided analysis of Manatū Hauora- New Zealand Cancer Registry data, Māori comprised roughly 3% of registered cases of WM between 2010 to 2020. The Committee considered there to be a lack of evidence to suggest there was a difference in age-standardised incidence or disease biology for Māori individuals compared to non-Māori individuals with WM in New Zealand.</p><p><em>Health benefit</em></p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the following evidence of the progression-free survival (PFS) that the currently funded treatment options can provide: </p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>BR can provide a median PFS of up to 69.5 months (<a href=""https://pubmed.ncbi.nlm.nih.gov/23433739/"" target=""_blank"">Rummel et al. Lancet. 2013;381:1203-103</a>).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>CDR can provide a median PFS of up to 34 months in the first-line setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/26359434/"" target=""_blank"">Kastritis et al. Blood). 2015;126:1392-4</a>) and up to 35 month in the R/R setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/28786474/"" target=""_blank"">Paludo et al. Br J Haematol. 2017;179:98-105</a>).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>R-CVP/R-CHOP can provide a median PFS of up to 30 months in the upfront setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/23433739/"" target=""_blank"">Rummel et al. Lancet. 2013;381:1203-103</a>).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>R-monotherapy can provide a median PFS of up to 20 months in the upfront setting and 20 months in the R/R setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/29856685/"" target=""_blank"">Dimopoulas et al N Engl J Med. 2018;378:2399-2410</a>).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that zanubrutinib is a second-generation inhibitor of Bruton’s tyrosine kinase (BTKi). Zanubrutinib binds with high affinity to the BTK target site, forming an irreversible covalent bond, thus preventing further BTK-mediated activity, hindering malignant B-cell proliferation and differentiation.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there is limited evidence to support the use of zanubrutinib in the first-line setting, with only 20 of the 201 participants in ASPEN receiving zanubrutinib in the first-line setting and the remaining participants having relapsed/refractory disease (<a href=""https://pubmed.ncbi.nlm.nih.gov/32731259/"" target=""_blank"">Tam et al. Blood. 2020;136:2038-50</a>; <a href=""https://pubmed.ncbi.nlm.nih.gov/32698195/"" target=""_blank"">Trotman et al. Blood. 2022;136:2027-37</a>). </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee previously considered there to be a class effect between BTKi therapies for the treatment of WM. The Committee considered that, based on the available evidence, both ibrutinib and zanubrutinib appeared to provide similar magnitudes of health benefit and similarly favourable safety profiles compared to funded chemotherapies. </p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there is no evidence of a difference in efficacy between zanubrutinib and ibrutinib. The Committee noted that there were greater rates of partial response rates when the individuals received zanubrutinib compared with ibrutinib, however the Committee considered that the response rate measure is not prognostic in WM and therefore did not translate into the PFS or OS benefit. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the supplier’s proposed treatment paradigms for individuals requiring first-line and R/R treatment for WM but considered both to be unsuitable. In regard to first line, the Committee considered that treatment options depend on whether BR is either going to be suitable or unsuitable for the individual, and that if BR was deemed unsuitable alternative options for individuals could include CDR, R-CVP, R-monotherapy or a BTKi if it was available. In regard to the R/R treatment setting, the Committee noted that less than 10% of individuals would receive retreatment of BR and that the preferred option for all individuals following first line immunochemotherapy would be a BTKi if it was available.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the ASPEN trial was a phase III randomised, double-blind, placebo-control trial comparing zanubrutinib monotherapy with rituximab monotherapy in 201 individuals with WM previously untreated (n=37) and treated (n=164) (<a href=""https://pubmed.ncbi.nlm.nih.gov/32731259/"" target=""_blank"">Tam et al. Blood. 2020; 146:2038-50</a>). </p><p class=""ql-indent-1"">1.14.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that individuals participating in the trial had to have received at least one prior line of treatment, or if individuals were treatment naïve, it was due to immunochemotherapy being inappropriate, and were reported to be due to cardiac, renal, infection or other reasons. Individuals had the <em>MYD88</em> mutation which is representative of over 90% of those with WM, however individuals with the wildtype gene or genetic testing were indeterminate received zanubrutinib in a non-randomised arm of the study (<a href=""https://pubmed.ncbi.nlm.nih.gov/33284944/"" target=""_blank"">Dimopoulos et al. Blood Adv. 2020:4 6009-18</a>). </p><p class=""ql-indent-1"">1.14.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the results of the final analysis of the ASPEN trial, where after a median follow up of 19.4 months, 79% of individuals remained on study treatment, and 89% remained on study. No individuals experienced a complete response. Overall 28% zanubrutinib group and 19% ibrutinib group (2-sided, p=0.09), 29% zanubrutinib group and 20% ibrutinib group (p =0.12) of the R/R group and 26% zanubrutinib group and 17% ibrutinib group (p =0.54) TN group were reported to experience a very good partial response, which was defined as monoclonal IgM detectable, ≥90% reduction in serum IgM level from baseline or normal serum IgM values, improvement in lymphadenopathy/splenomegaly if present at baseline, no new signs, or symptoms of active disease. The median time to experience the very good partial response was 4.7 months zanubrutinib and 5.1 months ibrutinib (p=0.17) for the R/R group and 5.6 months zanubrutinib and 22.1 months ibrutinib (p=0.35) for the TN group. The 18-month progression-free survival was reported to be 85% zanubrutinib and 84% ibrutinib and 18-month survival rate was 97% zanubrutinib and 93% ibrutinib. </p><p class=""ql-indent-1"">1.14.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the results of the toxicity and safety analysis of the ASPEN trial and noted that the incidence of adverse events involving atrial fibrillation/flutter, diarrhoea, contusion, muscle spasms, peripheral oedema and pneumonia occurred at ≥10% higher rates in individuals receiving ibrutinib compared with zanubrutinib and the incidence of neutropenia was ≥10% higher in individuals receiving zanubrutinib. The Committee noted that the higher incidence of neutropenia did not translate into a higher infection rate. </p><p class=""ql-indent-1"">1.14.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the long-term follow-up study of the ASPEN trial and noted that ibrutinib was associated with 19.4% of individuals experiencing an adverse event leading to discontinuation compared to 14.3% of individuals receiving zanubrutinib. The Committee noted the following proportions of individuals receiving either zanubrutinib or ibrutinib who experienced\xa0atrial fibrillation (7.9% zanubrutinib; 23.5% ibrutinib), diarrhoea (21.8% zanubrutinib; 34.7% ibrutinib), haemorrhage (55.4% zanubrutinib; 62.2% ibrutinib), major bleeding (7.9% zanubrutinib; 12.2% ibrutinib), hypertension (14.9% zanubrutinib; 25.5% ibrutinib), muscle spasm (10.9% zanubrutinib; 28.6% ibrutinib), localised infection (1.0% zanubrutinib; 11.2% ibrutinib), neutropenia (33.7% zanubrutinib; 19.4% ibrutinib), pneumonia (5% zanubrutinib; 18.4% ibrutinib), infection (grade ≥3) (78.2% zanubrutinib; 79.6% ibrutinib) (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430776/"" target=""_blank"">Dimopoulos et al. Hemasphere. 2922;6:1048-9</a>).</p><p class=""ql-indent-1"">1.14.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the results of the non-randomised arm of the ASPEN trial, and noted that 27% individuals with <em>MYD88 </em>wild-type were reported to have experienced a very good partial response when receiving zanubrutinib (<a href=""https://pubmed.ncbi.nlm.nih.gov/33284944/"" target=""_blank"">Dimopoulos et al. Blood Adv. 2020:4 6009-18</a>). The Committee noted that compared to <em>MYD88 </em>mutant WM individuals with <em>MYD88</em> wild type WM experienced lower rates of very good partial response. The Committee noted that Phase II study treating individuals with <em>MYD88</em> wild type WM with ibrutinib, and noted that individuals received less health benefit compared to individuals with <em>MYD88</em> mutant WM (<a href=""https://pubmed.ncbi.nlm.nih.gov/32931398/"" target=""_blank"" style=""font-size: 10pt;"">Treon et al. J Clin Oncol. 2021;39:565-575</a>). The Committee noted that the evidence was limited due to the small number of individuals with <em>MYD88</em> wild type WM, however considered that overall individuals with <em>MYD88</em> wild type WM receive less health benefit when receiving an BTKi therapy. </p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that there is high-quality evidence for what is a rare disease supporting the efficacy of zanubrutinib in the R/R setting. The Committee considered the evidence supporting the efficacy of zanubrutinib in the first line setting to be of lower quality due to the smaller number of participants in the ASPEN trial. The Committee considered that there was no evidence to suggest that zanubrutinib is inefficacious in the treatment naïve setting. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that BTKis have better safety profiles when compared to immunochemotherapy for the treatment of WM, however the Committee noted zanubrutinib has lower incidence of adverse events, highlighting the lower risk of atrial fibrillation/flutter in comparison to ibrutinib to be of particular importance as individuals with WM are usually older and more likely to be predisposed to atrial fibrillation/flutter. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the clinician-lead supporting submission requesting BTKi funding for individuals who are younger than 55 years old who relapse within five years of first-line immunochemotherapy and noted that requiring a second-line of treatment before the age of 55 years old is a rare situation. The Committee considered there to be a high probably that the disease course in this setting is more aggressive and considered the proposed SA criteria for individuals with R/R WM would be inclusive and appropriate for this situation. </p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that zanubrutinib would provide a health benefit to family, whānau and wider society, by allowing an individual to receive zanubrutinib at home, the lower toxicity profile, reducing the need to travel for individuals in rural areas, more time with family and whānau, and reduced chair time in chemotherapy units or hospital admission.</p><p><em>Suitability</em></p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that zanubrutinib is an oral medication that is administered twice daily. The Committee noted that funding zanubrutinib could reduce the need for individuals to travel to receive therapy at infusion facilities, as the funding alternatives to zanubrutinib are administered as infusions.</p><p><em>Cost and savings</em></p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that, based on the supplier-provided analysis of Manatū Hauora-New Zealand Cancer Registry data, there were an estimated 20 to 50 cases of newly diagnosed cases of WM per year in New Zealand and that the average annual growth in new cases over the period 2010 to 2020 was roughly 7% per annum.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the median time from diagnosis of WM to needing treatment is 5 to 10 years (<a href=""https://pubmed.ncbi.nlm.nih.gov/22451426/"" target=""_blank"">Kyle et al. Blood. 2012;119:4462-6</a>). The Committee noted that, due to the long natural history of the disease, and the population with WM being predominantly older adults, some individuals are dying from other causes.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the supplier’s estimate that 87% of newly diagnosed cases of WM would require treatment and noted this was based on a Spanish observational study of cases of WM who had IgM paraprotein concentrations of &gt;30g/L and percentage of clonal lymphocytes of &gt;20% in the marrow (<a href=""https://pubmed.ncbi.nlm.nih.gov/11736938/"" target=""_blank"">García-Sanz. Br J Haematol. 2001;115:575-82</a>). The Committee noted that a diagnosis of WM requires the proportion of clonal lymphocytes in the bone marrow to be &gt;10%, and there were no diagnostic criteria related to IgM paraprotein concentration. As such, the Committee considered that this cohort study was unlikely to be representative of the population with WM in New Zealand.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a previous CTAC discussion in October 2022, in the context of bortezomib for WM, that between 40 to 70 individuals with newly diagnosed or relapsed refractory WM could be eligible for treatment per year. The Committee considered those estimates could be appropriately applied to zanubrutinib for WM, noting these funding applications targeted the same population.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that zanubrutinib was unlikely to be used in combination with rituximab, as there was a lack of evidence that a zanubrutinib-rituximab combination would be any more efficacious than zanubrutinib alone. </p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered a cost-utility analysis submitted by the supplier which used rituximab monotherapy (R) as the comparator treatment for zanubrutinib in the first line setting and BR as the comparator in the relapsed/refractory setting. The Committee considered that the supplier-modelled comparators were not representative of the currently funded alternatives to zanubrutinib in either setting.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that, in a first line setting, zanubrutinib would most likely be considered for people with WM where BR chemotherapy is not suitable. The Committee considered that BR would not be suitable in approximately 40% of people requiring first-line treatment for WM. The Committee noted that currently either RCVP or CDR is the preferred treatment for those in which first-line BR is not suitable, with a roughly equal proportion of individuals between the two regimens. </p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that BR re-treatment would be suitable for less than 10% of people with relapsed/refractory WM, and that zanubrutinib would likely be considered for this group (regardless of performance status). The Committee noted that currently R, RCVP, or CDR are the preferred treatments for those in which second-line BR is not suitable, with a roughly equal proportion of individuals between the three regimens. </p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there was a modelled overall survival benefit in the supplier-provided cost-utility analyses for zanubrutinib. The Committee considered that there was limited overall survival data from ASPEN and relevant trials of comparators, and the available data did not indicate an apparent overall survival benefit associated with zanubrutinib. \xa0</p><p><em>Summary for assessment</em></p><p>1.29.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for zanubrutinib if it were to be funded in New Zealand for WM. </span>This<span style=""color: black;""> PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""font-size: 12px;"">PICO for zanubrutinib if it were to be funded in New Zealand for WM.\xa0\xa0</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000NoosS&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000aBD4"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for zanubrutinib in the treatment of Waldenström macroglobulinaemia (WM).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for zanubrutinib in the treatment of Waldenström macroglobulinaemia (WM).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 21 July 2023.', 'fs': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 21 July 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000NoosS2AR'}, 'Id': 'a0POZ00000NoosS2AR', 'Event_Date__c': '2023-11-21', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Friday 21 July 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Nov 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee recommended that zanubrutinib for the treatment of individuals with relapsed/refractory Waldenström macroglobulinaemia be listed with a <strong>medium</strong> priority within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Zanubrutinib</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application – relapsed/refractory Waldenström macroglobulinaemia (Lymphoplasmacytic Lymphoma)</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Prerequisites</strong><span style=""font-size: 9pt;""> (tick boxes where appropriate):</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has Waldenström Macroglobulinaemia/Lymphoplasmacytic Lymphoma requiring treatment; and</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has relapsed after, or is refractory to, previous line of treatment; and </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient is zanubrutinib naïve; and </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has good performance status.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal application</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Applications from any relevant practitioner. Approvals valid for 12 months. </span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Prerequisites</strong><span style=""font-size: 9pt;""> (tick boxes where appropriate) </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">No evidence of clinical disease progression and </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate, and the patient is benefiting from treatment.</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The health need for those experiencing relapsed/refractory (R/R) WM including those experiencing early relapse/refractory disease who have fewer treatment options following first line treatment.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The health benefit evidence and improved tolerability and safety of zanubrutinib compared to currently funded treatments for peoples with WM.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The improved suitability of an oral treatment option for individuals if used as a monotherapy.</p><p><br></p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for zanubrutinib in the treatment of Waldenström macroglobulinaemia (WM).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p><em>Māori impact</em></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, based on the supplier-provided analysis of Manatū Hauora- New Zealand Cancer Registry data, Māori comprised roughly 3% of registered cases of WM between 2010 to 2020. The Committee considered there to be a lack of evidence to suggest there was a difference in age-standardised incidence or disease biology for Māori individuals compared to non-Māori individuals with WM in New Zealand.</p><p><em>Background</em></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that at the November 2021 CaTSoP (now CTAC) meeting an application for ibrutinib, a first-generation Bruton’s tyrosine kinase inhibitor (BTKi) which is used as a continuous monotherapy for the treatment of WM was assessed and two recommendations were made. The Committee noted that CaTSoP recommended that ibrutinib for the treatment of first line and R/R WM be listed with a low and medium priority, respectively.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that at the October 2022 CTAC meeting an application for bortezomib, a proteosome inhibitor, which is used for a fixed duration in combination with other drugs for the treatment of WM, was assessed and bortezomib for the treatment of WM in the R/R setting was recommended to be listed with a medium priority. </p><p>Health need</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that WM is an incurable lymphoplasmacytic lymphoma infiltration of lymphoplasmacytic cells into the bone marrow and immunoglobulin M (IgM) monoclonal gammopathy. The Committee noted that WM is a relatively uncommon blood cancer, representing 2% of blood cancer cases. The Committee noted a supplier-provided analysis of Manatū Hauora- New Zealand Cancer Registry data, which suggested that in 2020, there were 40 newly diagnosed cases of WM in New Zealand. </p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the mean age of diagnosis with WM was roughly 68 years. The Committee noted that treatment is not required until the individual is experiencing symptoms, with a median time between diagnosis and\xa0treatment can be up to 5 to 10 years (<a href=""https://ashpublications.org/blood/article/119/19/4462/29975/Progression-in-smoldering-Waldenstrom"" target=""_blank"">Kyle et al. Blood. 2012;119:4462-6</a>). The Committee noted that there is an unmet health need for individuals who are unable to receive bendamustine-rituximab (BR) therapy, a relatively effective treatment for the condition but one that is typically reserved for people experiencing <a href=""https://jamanetwork.com/journals/jamaoncology/fullarticle/2432463"" target=""_blank"">good performance status</a>. </p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the currently funded treatment options for WM include BR, cyclophosphamide-dexamethasone-rituximab (CDR), rituximab-cyclophosphamide-vincristine-prednisone (R-CVP), cyclophosphamide-doxorubicin, vincristine, prednisone + rituximab (R-CHOP), rituximab-chlorambucil (R-Chlorambucil) and rituximab monotherapy. The Committee noted that BR is the preferred and most efficacious current treatment option for people experiencing <a href=""https://jamanetwork.com/journals/jamaoncology/fullarticle/2432463"" target=""_blank"">good performance status</a>, the other treatment regimens used in situations where BR is not a suitable option. </p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, based on the supplier-provided analysis of Manatū Hauora- New Zealand Cancer Registry data, Māori comprised roughly 3% of registered cases of WM between 2010 to 2020. The Committee considered there to be a lack of evidence to suggest there was a difference in age-standardised incidence or disease biology for Māori individuals compared to non-Māori individuals with WM in New Zealand.</p><p><em>Health benefit</em></p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the following evidence of the progression-free survival (PFS) that the currently funded treatment options can provide: </p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>BR can provide a median PFS of up to 69.5 months (<a href=""https://pubmed.ncbi.nlm.nih.gov/23433739/"" target=""_blank"">Rummel et al. Lancet. 2013;381:1203-103</a>).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>CDR can provide a median PFS of up to 34 months in the first-line setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/26359434/"" target=""_blank"">Kastritis et al. Blood). 2015;126:1392-4</a>) and up to 35 month in the R/R setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/28786474/"" target=""_blank"">Paludo et al. Br J Haematol. 2017;179:98-105</a>).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>R-CVP/R-CHOP can provide a median PFS of up to 30 months in the upfront setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/23433739/"" target=""_blank"">Rummel et al. Lancet. 2013;381:1203-103</a>).</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>R-monotherapy can provide a median PFS of up to 20 months in the upfront setting and 20 months in the R/R setting (<a href=""https://pubmed.ncbi.nlm.nih.gov/29856685/"" target=""_blank"">Dimopoulas et al N Engl J Med. 2018;378:2399-2410</a>).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that zanubrutinib is a second-generation inhibitor of Bruton’s tyrosine kinase (BTKi). Zanubrutinib binds with high affinity to the BTK target site, forming an irreversible covalent bond, thus preventing further BTK-mediated activity, hindering malignant B-cell proliferation and differentiation.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there is limited evidence to support the use of zanubrutinib in the first-line setting, with only 20 of the 201 participants in ASPEN receiving zanubrutinib in the first-line setting and the remaining participants having relapsed/refractory disease (<a href=""https://pubmed.ncbi.nlm.nih.gov/32731259/"" target=""_blank"">Tam et al. Blood. 2020;136:2038-50</a>; <a href=""https://pubmed.ncbi.nlm.nih.gov/32698195/"" target=""_blank"">Trotman et al. Blood. 2022;136:2027-37</a>). </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee previously considered there to be a class effect between BTKi therapies for the treatment of WM. The Committee considered that, based on the available evidence, both ibrutinib and zanubrutinib appeared to provide similar magnitudes of health benefit and similarly favourable safety profiles compared to funded chemotherapies. </p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there is no evidence of a difference in efficacy between zanubrutinib and ibrutinib. The Committee noted that there were greater rates of partial response rates when the individuals received zanubrutinib compared with ibrutinib, however the Committee considered that the response rate measure is not prognostic in WM and therefore did not translate into the PFS or OS benefit. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the supplier’s proposed treatment paradigms for individuals requiring first-line and R/R treatment for WM but considered both to be unsuitable. In regard to first line, the Committee considered that treatment options depend on whether BR is either going to be suitable or unsuitable for the individual, and that if BR was deemed unsuitable alternative options for individuals could include CDR, R-CVP, R-monotherapy or a BTKi if it was available. In regard to the R/R treatment setting, the Committee noted that less than 10% of individuals would receive retreatment of BR and that the preferred option for all individuals following first line immunochemotherapy would be a BTKi if it was available.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the ASPEN trial was a phase III randomised, double-blind, placebo-control trial comparing zanubrutinib monotherapy with rituximab monotherapy in 201 individuals with WM previously untreated (n=37) and treated (n=164) (<a href=""https://pubmed.ncbi.nlm.nih.gov/32731259/"" target=""_blank"">Tam et al. Blood. 2020; 146:2038-50</a>). </p><p class=""ql-indent-1"">1.14.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that individuals participating in the trial had to have received at least one prior line of treatment, or if individuals were treatment naïve, it was due to immunochemotherapy being inappropriate, and were reported to be due to cardiac, renal, infection or other reasons. Individuals had the <em>MYD88</em> mutation which is representative of over 90% of those with WM, however individuals with the wildtype gene or genetic testing were indeterminate received zanubrutinib in a non-randomised arm of the study (<a href=""https://pubmed.ncbi.nlm.nih.gov/33284944/"" target=""_blank"">Dimopoulos et al. Blood Adv. 2020:4 6009-18</a>). </p><p class=""ql-indent-1"">1.14.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the results of the final analysis of the ASPEN trial, where after a median follow up of 19.4 months, 79% of individuals remained on study treatment, and 89% remained on study. No individuals experienced a complete response. Overall 28% zanubrutinib group and 19% ibrutinib group (2-sided, p=0.09), 29% zanubrutinib group and 20% ibrutinib group (p =0.12) of the R/R group and 26% zanubrutinib group and 17% ibrutinib group (p =0.54) TN group were reported to experience a very good partial response, which was defined as monoclonal IgM detectable, ≥90% reduction in serum IgM level from baseline or normal serum IgM values, improvement in lymphadenopathy/splenomegaly if present at baseline, no new signs, or symptoms of active disease. The median time to experience the very good partial response was 4.7 months zanubrutinib and 5.1 months ibrutinib (p=0.17) for the R/R group and 5.6 months zanubrutinib and 22.1 months ibrutinib (p=0.35) for the TN group. The 18-month progression-free survival was reported to be 85% zanubrutinib and 84% ibrutinib and 18-month survival rate was 97% zanubrutinib and 93% ibrutinib. </p><p class=""ql-indent-1"">1.14.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the results of the toxicity and safety analysis of the ASPEN trial and noted that the incidence of adverse events involving atrial fibrillation/flutter, diarrhoea, contusion, muscle spasms, peripheral oedema and pneumonia occurred at ≥10% higher rates in individuals receiving ibrutinib compared with zanubrutinib and the incidence of neutropenia was ≥10% higher in individuals receiving zanubrutinib. The Committee noted that the higher incidence of neutropenia did not translate into a higher infection rate. </p><p class=""ql-indent-1"">1.14.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the long-term follow-up study of the ASPEN trial and noted that ibrutinib was associated with 19.4% of individuals experiencing an adverse event leading to discontinuation compared to 14.3% of individuals receiving zanubrutinib. The Committee noted the following proportions of individuals receiving either zanubrutinib or ibrutinib who experienced\xa0atrial fibrillation (7.9% zanubrutinib; 23.5% ibrutinib), diarrhoea (21.8% zanubrutinib; 34.7% ibrutinib), haemorrhage (55.4% zanubrutinib; 62.2% ibrutinib), major bleeding (7.9% zanubrutinib; 12.2% ibrutinib), hypertension (14.9% zanubrutinib; 25.5% ibrutinib), muscle spasm (10.9% zanubrutinib; 28.6% ibrutinib), localised infection (1.0% zanubrutinib; 11.2% ibrutinib), neutropenia (33.7% zanubrutinib; 19.4% ibrutinib), pneumonia (5% zanubrutinib; 18.4% ibrutinib), infection (grade ≥3) (78.2% zanubrutinib; 79.6% ibrutinib) (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430776/"" target=""_blank"">Dimopoulos et al. Hemasphere. 2922;6:1048-9</a>).</p><p class=""ql-indent-1"">1.14.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the results of the non-randomised arm of the ASPEN trial, and noted that 27% individuals with <em>MYD88 </em>wild-type were reported to have experienced a very good partial response when receiving zanubrutinib (<a href=""https://pubmed.ncbi.nlm.nih.gov/33284944/"" target=""_blank"">Dimopoulos et al. Blood Adv. 2020:4 6009-18</a>). The Committee noted that compared to <em>MYD88 </em>mutant WM individuals with <em>MYD88</em> wild type WM experienced lower rates of very good partial response. The Committee noted that Phase II study treating individuals with <em>MYD88</em> wild type WM with ibrutinib, and noted that individuals received less health benefit compared to individuals with <em>MYD88</em> mutant WM (<a href=""https://pubmed.ncbi.nlm.nih.gov/32931398/"" target=""_blank"" style=""font-size: 10pt;"">Treon et al. J Clin Oncol. 2021;39:565-575</a>). The Committee noted that the evidence was limited due to the small number of individuals with <em>MYD88</em> wild type WM, however considered that overall individuals with <em>MYD88</em> wild type WM receive less health benefit when receiving an BTKi therapy. </p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that there is high-quality evidence for what is a rare disease supporting the efficacy of zanubrutinib in the R/R setting. The Committee considered the evidence supporting the efficacy of zanubrutinib in the first line setting to be of lower quality due to the smaller number of participants in the ASPEN trial. The Committee considered that there was no evidence to suggest that zanubrutinib is inefficacious in the treatment naïve setting. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that BTKis have better safety profiles when compared to immunochemotherapy for the treatment of WM, however the Committee noted zanubrutinib has lower incidence of adverse events, highlighting the lower risk of atrial fibrillation/flutter in comparison to ibrutinib to be of particular importance as individuals with WM are usually older and more likely to be predisposed to atrial fibrillation/flutter. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the clinician-lead supporting submission requesting BTKi funding for individuals who are younger than 55 years old who relapse within five years of first-line immunochemotherapy and noted that requiring a second-line of treatment before the age of 55 years old is a rare situation. The Committee considered there to be a high probably that the disease course in this setting is more aggressive and considered the proposed SA criteria for individuals with R/R WM would be inclusive and appropriate for this situation. </p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that zanubrutinib would provide a health benefit to family, whānau and wider society, by allowing an individual to receive zanubrutinib at home, the lower toxicity profile, reducing the need to travel for individuals in rural areas, more time with family and whānau, and reduced chair time in chemotherapy units or hospital admission.</p><p><em>Suitability</em></p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that zanubrutinib is an oral medication that is administered twice daily. The Committee noted that funding zanubrutinib could reduce the need for individuals to travel to receive therapy at infusion facilities, as the funding alternatives to zanubrutinib are administered as infusions.</p><p><em>Cost and savings</em></p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that, based on the supplier-provided analysis of Manatū Hauora-New Zealand Cancer Registry data, there were an estimated 20 to 50 cases of newly diagnosed cases of WM per year in New Zealand and that the average annual growth in new cases over the period 2010 to 2020 was roughly 7% per annum.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that the median time from diagnosis of WM to needing treatment is 5 to 10 years (<a href=""https://pubmed.ncbi.nlm.nih.gov/22451426/"" target=""_blank"">Kyle et al. Blood. 2012;119:4462-6</a>). The Committee noted that, due to the long natural history of the disease, and the population with WM being predominantly older adults, some individuals are dying from other causes.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the supplier’s estimate that 87% of newly diagnosed cases of WM would require treatment and noted this was based on a Spanish observational study of cases of WM who had IgM paraprotein concentrations of &gt;30g/L and percentage of clonal lymphocytes of &gt;20% in the marrow (<a href=""https://pubmed.ncbi.nlm.nih.gov/11736938/"" target=""_blank"">García-Sanz. Br J Haematol. 2001;115:575-82</a>). The Committee noted that a diagnosis of WM requires the proportion of clonal lymphocytes in the bone marrow to be &gt;10%, and there were no diagnostic criteria related to IgM paraprotein concentration. As such, the Committee considered that this cohort study was unlikely to be representative of the population with WM in New Zealand.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a previous CTAC discussion in October 2022, in the context of bortezomib for WM, that between 40 to 70 individuals with newly diagnosed or relapsed refractory WM could be eligible for treatment per year. The Committee considered those estimates could be appropriately applied to zanubrutinib for WM, noting these funding applications targeted the same population.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that zanubrutinib was unlikely to be used in combination with rituximab, as there was a lack of evidence that a zanubrutinib-rituximab combination would be any more efficacious than zanubrutinib alone. </p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered a cost-utility analysis submitted by the supplier which used rituximab monotherapy (R) as the comparator treatment for zanubrutinib in the first line setting and BR as the comparator in the relapsed/refractory setting. The Committee considered that the supplier-modelled comparators were not representative of the currently funded alternatives to zanubrutinib in either setting.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that, in a first line setting, zanubrutinib would most likely be considered for people with WM where BR chemotherapy is not suitable. The Committee considered that BR would not be suitable in approximately 40% of people requiring first-line treatment for WM. The Committee noted that currently either RCVP or CDR is the preferred treatment for those in which first-line BR is not suitable, with a roughly equal proportion of individuals between the two regimens. </p><p>1.27.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that BR re-treatment would be suitable for less than 10% of people with relapsed/refractory WM, and that zanubrutinib would likely be considered for this group (regardless of performance status). The Committee noted that currently R, RCVP, or CDR are the preferred treatments for those in which second-line BR is not suitable, with a roughly equal proportion of individuals between the three regimens. </p><p>1.28.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that there was a modelled overall survival benefit in the supplier-provided cost-utility analyses for zanubrutinib. The Committee considered that there was limited overall survival data from ASPEN and relevant trials of comparators, and the available data did not indicate an apparent overall survival benefit associated with zanubrutinib. \xa0</p><p><em>Summary for assessment</em></p><p>1.29.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for zanubrutinib if it were to be funded in New Zealand for WM. </span>This<span style=""color: black;""> PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><span style=""font-size: 12px;"">PICO for zanubrutinib if it were to be funded in New Zealand for WM.\xa0\xa0</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000NoosS&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000aBD4"" alt=""image.png""></img></p>', 'Status_History__c': 'a13OZ000004HZANYA4'}, 'change': None}]",May 2023,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2024', 'fs': 'Jan 2024', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000NoosT2AR'}, 'Id': 'a0POZ00000NoosT2AR', 'Event_Date__c': '2024-01-17', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jan 2024', 'Status_History__c': 'a13OZ000005kD7VYAU'}, 'change': None}]",Jan 2024,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
